JP2015530390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530390A5 JP2015530390A5 JP2015532042A JP2015532042A JP2015530390A5 JP 2015530390 A5 JP2015530390 A5 JP 2015530390A5 JP 2015532042 A JP2015532042 A JP 2015532042A JP 2015532042 A JP2015532042 A JP 2015532042A JP 2015530390 A5 JP2015530390 A5 JP 2015530390A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- loop
- nos
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- 235000001014 amino acid Nutrition 0.000 claims 27
- 229920001184 polypeptide Polymers 0.000 claims 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 229940024606 amino acid Drugs 0.000 claims 23
- 150000001413 amino acids Chemical class 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 9
- 108010056852 Myostatin Proteins 0.000 claims 9
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 229910052698 phosphorus Inorganic materials 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000000663 muscle cell Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 102100034134 Activin receptor type-1B Human genes 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 102000002090 Fibronectin type III Human genes 0.000 claims 1
- 108050009401 Fibronectin type III Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000004190 glucose uptake Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 102000028557 immunoglobulin binding proteins Human genes 0.000 claims 1
- 108091009323 immunoglobulin binding proteins Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261700697P | 2012-09-13 | 2012-09-13 | |
| US61/700,697 | 2012-09-13 | ||
| US201361780005P | 2013-03-13 | 2013-03-13 | |
| US61/780,005 | 2013-03-13 | ||
| PCT/US2013/059458 WO2014043344A1 (en) | 2012-09-13 | 2013-09-12 | Fibronectin based scaffold domain proteins that bind to myostatin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018101646A Division JP6793680B2 (ja) | 2012-09-13 | 2018-05-28 | ミオスタチンと結合するフィブロネクチンベースの足場ドメインタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530390A JP2015530390A (ja) | 2015-10-15 |
| JP2015530390A5 true JP2015530390A5 (enExample) | 2016-10-27 |
| JP6346895B2 JP6346895B2 (ja) | 2018-06-20 |
Family
ID=49253416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532042A Active JP6346895B2 (ja) | 2012-09-13 | 2013-09-12 | ミオスタチンと結合するフィブロネクチンベースの足場ドメインタンパク質 |
| JP2018101646A Active JP6793680B2 (ja) | 2012-09-13 | 2018-05-28 | ミオスタチンと結合するフィブロネクチンベースの足場ドメインタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018101646A Active JP6793680B2 (ja) | 2012-09-13 | 2018-05-28 | ミオスタチンと結合するフィブロネクチンベースの足場ドメインタンパク質 |
Country Status (33)
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| EP2576615B1 (en) | 2010-05-26 | 2016-03-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| ES2608835T3 (es) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| LT3835310T (lt) | 2012-09-13 | 2024-04-25 | Bristol-Myers Squibb Company | Fibronektino pagrindo karkaso domeno baltymai, kurie rišasi prie miostatino |
| JP6475639B2 (ja) | 2013-01-25 | 2019-02-27 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン |
| EP2951206A2 (en) | 2013-02-01 | 2015-12-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| ES2689372T3 (es) | 2013-02-06 | 2018-11-13 | Bristol-Myers Squibb Company | Proteínas de dominio de fibronectina tipo III con solubilidad mejorada |
| ES2870802T3 (es) | 2013-02-12 | 2021-10-27 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| WO2015143199A1 (en) | 2014-03-20 | 2015-09-24 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type iii domains |
| EP3647322B1 (en) | 2014-03-20 | 2021-10-20 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
| WO2015161108A1 (en) * | 2014-04-16 | 2015-10-22 | The Scripps Research Institute | Pparg modulators for treatment of osteoporosis |
| US11072681B2 (en) | 2014-07-28 | 2021-07-27 | The Regents Of The University Of California | Compositions and methods of making polymerizing nucleic acids |
| US10980744B2 (en) | 2014-08-08 | 2021-04-20 | The Regents Of The University Of California | High density peptide polymers |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| HRP20201756T8 (hr) | 2014-11-21 | 2021-08-20 | Bristol-Myers Squibb Company | Antitijela koja sadrže modificirane regije teškog lanca |
| DK3221363T3 (da) | 2014-11-21 | 2020-08-10 | Bristol Myers Squibb Co | Antistoffer mod cd73 og anvendelser deraf |
| CN107207379B (zh) | 2014-11-25 | 2021-08-10 | 百时美施贵宝公司 | 用于生物制品的18f-放射性标记的方法和组合物 |
| EP3224277B1 (en) | 2014-11-25 | 2020-08-26 | Bristol-Myers Squibb Company | Novel pd-l1 binding polypeptides for imaging |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US10993993B2 (en) * | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
| LT3303396T (lt) | 2015-05-29 | 2023-01-10 | Bristol-Myers Squibb Company | Antikūnai prieš ox40 ir jų panaudojimo būdai |
| MX2017016502A (es) | 2015-06-29 | 2018-03-12 | Univ Rockefeller | Anticuerpos contra cd40 con actividad agonista mejorada. |
| US20180228925A1 (en) * | 2015-08-28 | 2018-08-16 | University Of Massachusetts | Quantifying Net Axonal Transport in Motor Neuron Pathologies |
| ES2809125T3 (es) * | 2015-09-23 | 2021-03-03 | Bristol Myers Squibb Co | Moléculas de armazón a base de fibronectina de unión a glipicano-3 |
| JP2018536404A (ja) | 2015-11-09 | 2018-12-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| KR20180118725A (ko) | 2016-03-04 | 2018-10-31 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| CA3016534A1 (en) | 2016-03-04 | 2017-09-08 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| RU2613420C1 (ru) * | 2016-04-13 | 2017-03-16 | Сергей Михайлович Юдин | Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3455243B1 (en) | 2016-05-11 | 2021-03-24 | Cytiva BioProcess R&D AB | Separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| KR102397783B1 (ko) | 2016-06-01 | 2022-05-12 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-l1 결합 폴리펩티드에 의한 pet 영상화 |
| CA3032826A1 (en) * | 2016-08-03 | 2018-02-08 | Nextcure, Inc. | Compositions and methods for modulating lair signal transduction |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| EP3549595A4 (en) * | 2016-12-05 | 2020-07-22 | Otsuka Pharmaceutical Co., Ltd. | COMPOSITION INHIBITING AMYOTROPHY |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| TWI897843B (zh) * | 2017-05-03 | 2025-09-21 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
| IL270596B1 (en) | 2017-05-25 | 2025-09-01 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant region for use in treating cancer |
| KR102813744B1 (ko) | 2017-12-27 | 2025-05-28 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd40 항체 및 그의 용도 |
| KR20200058322A (ko) | 2018-01-25 | 2020-05-27 | 아이-맵 바이오파마 유에스 리미티드 | 항-pd-l1 항체 및 il-7 융합체 |
| CN108593615A (zh) * | 2018-05-02 | 2018-09-28 | 浠思（上海）生物技术有限公司 | 利用htrf一步法筛选pd1/pd-l1阻断剂的方法 |
| JP7051656B2 (ja) | 2018-09-28 | 2022-04-11 | 三菱重工コンプレッサ株式会社 | タービンステータ、蒸気タービン、及び仕切板 |
| TW202033555A (zh) | 2018-11-16 | 2020-09-16 | 美商必治妥美雅史谷比公司 | 抗nkg2a抗體及其用途 |
| KR20210096167A (ko) | 2018-11-28 | 2021-08-04 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
| WO2021183428A1 (en) | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
| US11566346B2 (en) | 2020-06-25 | 2023-01-31 | Philip David Rodley | Protein scaffold |
| CA3202089A1 (en) * | 2020-11-20 | 2022-05-27 | Zoetis Services Llc | Bovine antibody variants |
| EP4503923A1 (en) | 2022-04-04 | 2025-02-12 | The Regents of the University of California | Genetic complementation compositions and methods |
| WO2025177263A1 (en) | 2024-02-25 | 2025-08-28 | Biohaven Therapeutics Ltd. | Myostatin-binding proteins |
| WO2025219859A1 (en) | 2024-04-14 | 2025-10-23 | Biohaven Therapeutics Ltd. | Combination therapy to treat overweight, obesity, and related health conditions |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US6018030A (en) | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
| US5641648A (en) | 1986-11-04 | 1997-06-24 | Protein Polymer Technologies, Inc. | Methods for preparing synthetic repetitive DNA |
| US5514581A (en) | 1986-11-04 | 1996-05-07 | Protein Polymer Technologies, Inc. | Functional recombinantly prepared synthetic protein polymer |
| US5770697A (en) | 1986-11-04 | 1998-06-23 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
| US5589173A (en) | 1986-11-04 | 1996-12-31 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| US5792742A (en) | 1991-06-14 | 1998-08-11 | New York University | Fibrin-binding peptide fragments of fibronectin |
| WO2002081494A1 (en) | 2001-03-26 | 2002-10-17 | Sirna Therapeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| WO1994017097A1 (en) | 1993-01-19 | 1994-08-04 | Regents Of The University Of Minnesota | Synthetic fibronectin fragments as inhibitors of retroviral infections |
| US6673534B1 (en) | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US20030074680A1 (en) | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| PT971946E (pt) | 1997-01-21 | 2006-11-30 | Gen Hospital Corp | Selecção de proteínas utilizando fusões arn-proteína |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US7749498B2 (en) | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| DE69941116D1 (de) | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
| PT1137941E (pt) | 1998-12-10 | 2009-10-15 | Brystol Myers Squibb Company | Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| JP2003528632A (ja) | 2000-03-31 | 2003-09-30 | インスティティ・パスツール | 血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法 |
| AU2001277867B2 (en) | 2000-07-11 | 2006-12-07 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
| US7598352B2 (en) | 2000-11-17 | 2009-10-06 | University Of Rochester | Method of identifying polypeptide monobodies which bind to target proteins and use thereof |
| EP1572718A4 (en) | 2001-04-04 | 2006-03-15 | Univ Rochester | ALPHA NU BETA-3 INTEGRIN BINDING POLYPEPTIDE ANTIBODY AND THEIR USE |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| CN102584997A (zh) | 2002-11-08 | 2012-07-18 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子-α的单结构域抗体及其用途 |
| US20080220049A1 (en) | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
| KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
| SI1729795T1 (sl) | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
| AU2005227896B2 (en) | 2004-03-23 | 2008-11-13 | Eli Lilly And Company | Anti-myostatin antibodies |
| WO2005118646A2 (en) | 2004-04-26 | 2005-12-15 | Centocor, Inc. | Epitope directed selection of antibodies to murine tissue factor |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| EP1804751A2 (en) | 2004-10-04 | 2007-07-11 | QLT USA, Inc. | Ocular delivery of polymeric delivery formulations |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| EA201100642A1 (ru) | 2005-04-25 | 2011-12-30 | Пфайзер Инк. | Антитела к миостатину |
| PT2407486T (pt) | 2005-08-19 | 2018-02-21 | Univ Pennsylvania | Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8 |
| CN101277976B (zh) | 2005-10-06 | 2012-04-11 | 伊莱利利公司 | 抗肌抑制素抗体 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US20070149458A1 (en) | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| UA98308C2 (en) | 2006-09-05 | 2012-05-10 | Эли Лилли Энд Компани | Anti-myostatin antibody |
| WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| CA2670471A1 (en) | 2006-11-22 | 2008-06-05 | Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
| WO2008097497A2 (en) | 2007-02-02 | 2008-08-14 | Adnexus, A Bristol-Myers Squibb R & D Company | Vegf pathway blockade |
| EP2162540A2 (en) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US20090176654A1 (en) | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| US20100285000A1 (en) | 2007-08-20 | 2010-11-11 | Bristol-Myers Squibb Company | Use of vegfr-2 inhibitors for treating metastatic cancer |
| KR100857861B1 (ko) * | 2007-10-15 | 2008-09-11 | 주식회사 바이오리더스 | Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물 |
| US8633297B2 (en) | 2007-10-31 | 2014-01-21 | Medimmune, Llc | Protein scaffolds |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| EP2217274A1 (en) | 2007-11-28 | 2010-08-18 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with mtor inhibitors |
| JP2011507529A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Ｍ１３ファージのｐＩＸへの融合を介する代替の足場タンパク質融合ファージ提示 |
| AU2008345424A1 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| CN102007145A (zh) | 2008-02-14 | 2011-04-06 | 百时美施贵宝公司 | 基于结合egfr的工程化蛋白质的靶向治疗剂 |
| MX2010011957A (es) | 2008-05-02 | 2011-03-04 | Novartis Ag Star | Moleculas de union basadas en fibronectina mejoradas y usos de las mismas. |
| EP2799448A1 (en) | 2008-05-22 | 2014-11-05 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
| CN102307896B (zh) | 2008-10-31 | 2016-10-12 | 森托科尔奥索生物科技公司 | 基于iii型纤连蛋白结构域的支架组合物、方法及用途 |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| WO2010069913A1 (en) | 2008-12-16 | 2010-06-24 | Novartis Ag | Yeast display systems |
| TW201029662A (en) * | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
| US20100210511A1 (en) | 2009-02-11 | 2010-08-19 | Bristol-Myers Squibb Company | Combination VEGFR2 Therapy with Temozolomide |
| CA2752211C (en) | 2009-02-12 | 2020-03-24 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| US8067201B2 (en) | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
| EP2464663A4 (en) | 2009-08-13 | 2013-05-29 | Massachusetts Inst Technology | MANIPULATED PROTEINS WITH MUTANT FIBRONECTIN DOMAINS |
| ES2860453T3 (es) | 2009-10-30 | 2021-10-05 | Novartis Ag | Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III |
| WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
| WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
| WO2011100700A2 (en) | 2010-02-12 | 2011-08-18 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
| BR112012019881A2 (pt) | 2010-02-18 | 2017-06-27 | Bristol Myers Squibb Co | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 |
| EP3424949A1 (en) | 2010-04-13 | 2019-01-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
| AU2011240620A1 (en) | 2010-04-13 | 2012-10-18 | Medimmune, Llc | Fibronectin type III domain-based multimeric scaffolds |
| HUE029622T2 (en) | 2010-04-30 | 2017-03-28 | Janssen Biotech Inc | Stabilized fibronectin domain compositions, methods and uses |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| EP2576615B1 (en) | 2010-05-26 | 2016-03-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| AU2011283646B2 (en) | 2010-07-30 | 2015-07-09 | Novartis Ag | Fibronectin cradle molecules and libraries thereof |
| CA2808382A1 (en) | 2010-08-16 | 2012-02-23 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| EP2655411A1 (en) * | 2010-12-22 | 2013-10-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind il-23 |
| ES2608835T3 (es) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| WO2012158739A1 (en) | 2011-05-17 | 2012-11-22 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
| EP2709669A1 (en) | 2011-05-17 | 2014-03-26 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| EP2761066B1 (en) | 2011-09-27 | 2018-12-05 | Janssen Biotech, Inc. | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
| US9453080B2 (en) | 2012-06-11 | 2016-09-27 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| WO2013186719A1 (en) | 2012-06-15 | 2013-12-19 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| LT3835310T (lt) | 2012-09-13 | 2024-04-25 | Bristol-Myers Squibb Company | Fibronektino pagrindo karkaso domeno baltymai, kurie rišasi prie miostatino |
| TWI897843B (zh) | 2017-05-03 | 2025-09-21 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
-
2013
- 2013-09-12 LT LTEP20206702.1T patent/LT3835310T/lt unknown
- 2013-09-12 RS RS20210753A patent/RS62009B1/sr unknown
- 2013-09-12 MY MYPI2015700817A patent/MY172863A/en unknown
- 2013-09-12 DK DK13767190.5T patent/DK2895503T3/da active
- 2013-09-12 HU HUE19162848A patent/HUE054699T2/hu unknown
- 2013-09-12 LT LTEP19162848.6T patent/LT3564258T/lt unknown
- 2013-09-12 EP EP20206702.1A patent/EP3835310B1/en active Active
- 2013-09-12 UY UY0001035027A patent/UY35027A/es active IP Right Grant
- 2013-09-12 PT PT191628486T patent/PT3564258T/pt unknown
- 2013-09-12 US US14/025,253 patent/US8933199B2/en active Active
- 2013-09-12 SM SM20240214T patent/SMT202400214T1/it unknown
- 2013-09-12 SI SI201331889T patent/SI3564258T1/sl unknown
- 2013-09-12 SG SG10201913685YA patent/SG10201913685YA/en unknown
- 2013-09-12 RS RS20190618A patent/RS58801B1/sr unknown
- 2013-09-12 SI SI201331453T patent/SI2895503T1/sl unknown
- 2013-09-12 ES ES13767190T patent/ES2727453T3/es active Active
- 2013-09-12 EP EP13767190.5A patent/EP2895503B1/en active Active
- 2013-09-12 SG SG11201501741YA patent/SG11201501741YA/en unknown
- 2013-09-12 PL PL13767190T patent/PL2895503T3/pl unknown
- 2013-09-12 AU AU2013315482A patent/AU2013315482B2/en active Active
- 2013-09-12 HU HUE13767190A patent/HUE043482T2/hu unknown
- 2013-09-12 PL PL19162848T patent/PL3564258T3/pl unknown
- 2013-09-12 PL PL20206702.1T patent/PL3835310T3/pl unknown
- 2013-09-12 NZ NZ628446A patent/NZ628446A/en unknown
- 2013-09-12 JP JP2015532042A patent/JP6346895B2/ja active Active
- 2013-09-12 IL IL270110A patent/IL270110B/en unknown
- 2013-09-12 BR BR112015005466-8A patent/BR112015005466B1/pt active IP Right Grant
- 2013-09-12 DK DK20206702.1T patent/DK3835310T3/da active
- 2013-09-12 MY MYPI2019003412A patent/MY189682A/en unknown
- 2013-09-12 CN CN201380056757.6A patent/CN104768969B/zh active Active
- 2013-09-12 TW TW107106852A patent/TWI694085B/zh active
- 2013-09-12 CN CN201810199962.2A patent/CN108409856B/zh active Active
- 2013-09-12 KR KR1020227025177A patent/KR102751864B1/ko active Active
- 2013-09-12 PT PT202067021T patent/PT3835310T/pt unknown
- 2013-09-12 KR KR1020157009067A patent/KR102187714B1/ko active Active
- 2013-09-12 HR HRP20190845TT patent/HRP20190845T1/hr unknown
- 2013-09-12 TW TW102133033A patent/TWI633117B/zh active
- 2013-09-12 EA EA201590543A patent/EA033536B1/ru not_active IP Right Cessation
- 2013-09-12 ES ES19162848T patent/ES2879387T3/es active Active
- 2013-09-12 SG SG10201701970TA patent/SG10201701970TA/en unknown
- 2013-09-12 SI SI201332082T patent/SI3835310T1/sl unknown
- 2013-09-12 DK DK19162848.6T patent/DK3564258T3/da active
- 2013-09-12 CA CA2884730A patent/CA2884730C/en active Active
- 2013-09-12 KR KR1020207034555A patent/KR102424590B1/ko active Active
- 2013-09-12 ES ES20206702T patent/ES2984405T3/es active Active
- 2013-09-12 LT LTEP13767190.5T patent/LT2895503T/lt unknown
- 2013-09-12 UY UY0001040128A patent/UY40128A/es not_active Application Discontinuation
- 2013-09-12 RS RS20240550A patent/RS65556B1/sr unknown
- 2013-09-12 MX MX2019008391A patent/MX390017B/es unknown
- 2013-09-12 WO PCT/US2013/059458 patent/WO2014043344A1/en not_active Ceased
- 2013-09-12 IL IL294314A patent/IL294314A/en unknown
- 2013-09-12 PT PT13767190T patent/PT2895503T/pt unknown
- 2013-09-12 FI FIEP20206702.1T patent/FI3835310T3/fi active
- 2013-09-12 PE PE2015000354A patent/PE20150954A1/es active IP Right Grant
- 2013-09-12 EP EP24163980.6A patent/EP4397675A3/en active Pending
- 2013-09-12 EP EP19162848.6A patent/EP3564258B1/en active Active
- 2013-09-12 HR HRP20240676TT patent/HRP20240676T1/hr unknown
- 2013-09-12 MX MX2015002894A patent/MX366666B/es active IP Right Grant
- 2013-09-12 US US14/025,307 patent/US8853154B2/en active Active
- 2013-09-12 HU HUE20206702A patent/HUE067383T2/hu unknown
-
2014
- 2014-05-12 US US14/275,542 patent/US8993265B2/en active Active
- 2014-09-09 US US14/481,641 patent/US9493546B2/en active Active
-
2015
- 2015-02-24 PH PH12015500397A patent/PH12015500397B1/en unknown
- 2015-02-26 US US14/632,436 patent/US9662373B2/en active Active
- 2015-02-27 CL CL2015000500A patent/CL2015000500A1/es unknown
- 2015-03-03 ZA ZA2015/01457A patent/ZA201501457B/en unknown
- 2015-03-04 IL IL23755915A patent/IL237559B/en active IP Right Grant
- 2015-03-06 TN TNP2015000086A patent/TN2015000086A1/fr unknown
-
2016
- 2016-09-30 US US15/282,277 patent/US10245302B2/en active Active
-
2017
- 2017-04-19 US US15/491,271 patent/US10406212B2/en active Active
-
2018
- 2018-02-22 AU AU2018201273A patent/AU2018201273B2/en active Active
- 2018-05-28 JP JP2018101646A patent/JP6793680B2/ja active Active
-
2019
- 2019-02-14 US US16/276,156 patent/US11813315B2/en active Active
-
2021
- 2021-06-23 HR HRP20210990TT patent/HRP20210990T1/hr unknown
-
2023
- 2023-10-06 US US18/482,248 patent/US20240316161A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015530390A5 (enExample) | ||
| HRP20190845T1 (hr) | Proteini okosnične domene na bazi fibronektina koji se vežu na miostatin | |
| EP3004152B1 (en) | Designed ankyrin repeat proteins binding to hepatocyte growth factor | |
| CN115003689A (zh) | 具有改变的表面残基的经设计的锚蛋白重复结构域 | |
| JP2014510518A5 (enExample) | ||
| JP7623273B2 (ja) | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 | |
| JP2012531212A5 (enExample) | ||
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| FI2968461T3 (fi) | Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi | |
| JP2002508183A5 (enExample) | ||
| JP2014504150A5 (enExample) | ||
| AU2016262845A1 (en) | Anti-cancer fusion polypeptide | |
| BR112020004567A2 (pt) | polipeptídeos para o tratamento de doenças | |
| JP2014510519A5 (enExample) | ||
| JP2016519051A5 (enExample) | ||
| KR20200123132A (ko) | 융합 단백질 | |
| JP2006502702A5 (enExample) | ||
| CN103118708B (zh) | 用于纯化聚乙二醇化的促红细胞生成素的方法 | |
| CN111153965A (zh) | 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用 | |
| KR101323846B1 (ko) | 타겟 친화도가 유지되고 안정성이 개선된 ｄ－앱타이드 | |
| WO2023064914A1 (en) | Compositions and methods for purifying biological fluids | |
| JP2015515264A5 (enExample) | ||
| RU2010125678A (ru) | Способ получения рекомбинантной вакцины | |
| CN106040196A (zh) | 一种凝血因子ⅷ亲和层析树脂的制备方法 | |
| CN104672329B (zh) | 一种蛋白质 |